Estrella Immunopharma, Inc. (ESLA) stock
ESLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ESLAW
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.33−0.05 (-12.74%)
Close on Nov 17, 2026Market cap $14.42MP/E –Yield –
Estrella Immunopharma r&d expenses
Research and development expenses are spending on new products and technology.
Estrella Immunopharma's R&D Expenses for the twelve months ending Jun 30, 2024 was $4.11M. For fiscal 2024 it was $4.11M.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | $4.11M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026CQ3 2025 | Jun 30, 2026 | $2.80M | +479.3% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $3.53M | – |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $25.00K | – |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $75.46K | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $483.47K | – |
See a number that looks wrong?